GRAIL spin-off complete; GRAIL to begin regular way trading as "GRAL" on June 25Illumina to issue second quarter 2024 results on August 6; leadership to present Strategy Update on August 13SAN DIEGO, June 24, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the successful completion of the spin-off of GRAIL. This milestone follows the company's previously announced plans to divest GRAIL, and GRAIL is now a public and independent company. GRAIL will begin regular way trading on Nasdaq on Tu ...

Illumina, Inc. (ILMN) has progressed in genomic research with the recent launch of DRAGEN v4.3. This is the latest version of the company’s DRAGEN software line.This new release marks a significant advancement in the field of next-generation sequencing (NGS), featuring an advanced multigenome mapping technology. This innovation allows for the inclusion of 128 samples from 26 different ancestries, thus capturing a broader spectrum of genetic diversity and reducing ancestry bias.The ability to create custom D ...

(Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesOn June 3, 2024, Illumina’s (NASDAQ: ILMN, $109.82, Market Capitalization: $17.5 billion) board of directors approved the spin-off of its wholly owned subsidiary GRAIL, Inc. and shared the details on the timeline.Earlier on May 6, 2024, ILMN had filed the initial Form 10 disclosing the deal overview and separation agreement. Subsequently, on June 3, 2024, ILMN submitted an amended Form 10 d ...

"We are excited to launch DRAGEN v4.3, with significant enhancements and additions to our analysis tools, empowering researchers and geneticists to maximize the value of the genome," said Rami Mehio, head of Software & Informatics at Illumina. "DRAGEN v4.3 includes our next-generation and most accurate multigenome mapping technology, built-in mosaic calling, advancements in machine learning, and the ability to genotype difficult genes to unlock deeper insights into the human genome with greater power, accur ...

Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Illumina Inc (ILMN) - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering.This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. ...

INDIA - 2023/12/16: In this photo illustration, the Illumina logo is seen displayed on a mobile ... [+] phone screen. (Photo Illustration by Idrees Abbas/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesIllumina stock (NASDAQ: ILMN) saw a 7% rise on Thursday, June 6, faring better than its peer — Mettler-Toledo stock – down 1%. The rise in ILMN stock can primarily be attributed to the company’s decision to spin off its blood testing company – Grail. Illumina acquired Grail in ...

The New Jersey representative bought and sold some stock in April.On April 19, U.S. Rep. Thomas Kean Jr., R-N.J., bought shares of Illumina (ILMN -0.89%) and sold shares of Nike (NKE 0.87%), according to a May 31 filing. Although it's unclear exactly how many shares were involved in the trades, the amount reported for each transaction was between $1,001 and $15,000. From April 19 through the close of trading yesterday, Illumina stock had fallen 9.1%, and Nike stock was essentially flat, down less than 0.01% ...

"We are excited to deliver for our NextSeq 1000/2000 customers improved sequencing with faster run times, better quality, and higher output—all at lower cost per kit," said Jason Johnson, head of Global Product Management at Illumina. "XLEAP-SBS chemistry on NextSeq 1000/2000 will enable labs to perform bigger NGS projects without raising the budget, and facilitate greater adoption of multiomic approaches."In March, the company launched its P4 flow cell (highest output of 540 Gb) with XLEAP-SBS chemistry fo ...

Core Viewpoint - Illumina, Inc. has announced the spin-off of GRAIL, which is expected to be completed on June 24, 2024, marking a significant milestone for the company as it focuses on advancing genomics innovation and improving human health [1][2]. Stock Distribution - Illumina shareholders will receive one share of GRAIL common stock for every six shares of Illumina common stock held as of June 13, 2024, with a total distribution of 85.5% of GRAIL's outstanding common stock [2][3]. - Illumina will retain a 14.5% minority share in GRAIL following the spin-off [2]. Trading Details - "When-issued" trading for GRAIL common stock is expected to begin on or about June 12, 2024, under the ticker symbol "GRAL WI," transitioning to regular trading on June 25, 2024 [5]. - Illumina shares will trade in two markets: "regular way" with entitlement to GRAIL shares and "ex-distribution" without entitlement [5][6]. Fractional Shares - Fractional shares of GRAIL will not be distributed; instead, they will be aggregated and sold in the open market, with net proceeds distributed in cash to shareholders entitled to fractional shares [3]. Tax Implications - U.S. shareholders of Illumina generally will not recognize gain or loss from the distribution of GRAIL shares, except for cash received for fractional shares [4]. Company Information - Illumina is a leader in DNA sequencing and array-based technologies, focusing on improving human health through genomics [9]. - GRAIL aims to detect cancer early using advanced technologies, contributing to the fight against cancer [10].

Core Viewpoint - Illumina, Inc. has appointed Everett Cunningham as Chief Commercial Officer, effective June 10, 2024, to enhance its global commercial organization and drive growth in the healthcare sector [1][2]. Group 1: Appointment Details - Everett Cunningham will be responsible for building, guiding, and managing Illumina's global commercial organization [2]. - Cunningham has over 20 years of commercial leadership experience in healthcare technology, life sciences, and pharmaceuticals [1][2]. - He previously served as Chief Commercial Officer at Exact Sciences, overseeing marketing, sales, and customer service functions [2]. Group 2: Leadership Experience - Prior to his role at Exact Sciences, Cunningham held senior leadership positions at Quest Diagnostics, GE Healthcare, and Pfizer, where he spent 21 years [2]. - He has a proven track record in driving operational excellence, delivering top-line results, and expanding into new markets [2]. Group 3: Company Vision - Illumina's CEO, Jacob Thaysen, expressed enthusiasm for Cunningham's appointment, highlighting his experience and passion for addressing significant healthcare challenges [2]. - The company aims to leverage Cunningham's leadership to capitalize on its position in next-generation sequencing and meet customer needs [2].